Meeting
2020 Genitourinary Cancers Symposium
Discordance of HER2 expression in distant metastatic tumors (MTs) versus primary tumors (PTs) in urothelial carcinoma (UC).
Authors
Claud Grigg
Levine Cancer Institute, Atrium Health, Charlotte, NC
Claud Grigg , Chad Livasy , Jiaxian He , Aaron Hartman , Peter E. Clark , Derek Raghavan , Earle Frederick Burgess
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 550)
Abstract #
550
Poster Bd #
L9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
First Author: Xingliang Tan
Poster
2019 Gastrointestinal Cancers Symposium
Comparison of HER2 expression by immunohistochemistry and HER2 copy number by digital PCR in tumor tissue during treatment with trastuzumab in the prospective cohort of metastatic HER2-positive gastric cancer patients.
First Author: Naoki Takahashi
Poster
2024 ASCO Annual Meeting
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
First Author: Piotr Jan Wysocki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura